NCT03858634 - A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

April 1, 2020

Study Completion Date

June 8, 2020

Conditions

Chronic Idiopathic UrticariaChronic Idiopathic PruritusLichen PlanusLichen Simplex ChronicusPlaque Psoriasis

Interventions

DRUG

KPL-716

A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.

DRUG

Placebo

Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.

Trial Locations (14)

10012

Site 123, New York

33172

Site 113, Sweetwater

36207

Site 106, Anniston

46168

Site 112, Plainfield

48059

Site 109, Fort Gratiot

61761

Site 105, Normal

70115

Site 119, New Orleans

71913

Site 114, Hot Springs

78213

Site 101, San Antonio

78660

Site 104, Pflugerville

85032

Site 110, Phoenix

90045

Site 103, Los Angeles

99202

Site 122, Spokane

02919

Site 115, Johnston